Published in Blood on June 04, 2010
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood (2013) 1.69
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47
SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets (2011) 1.46
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia (2011) 1.34
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract (2012) 1.34
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res (2011) 1.32
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res (2011) 1.31
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J (2012) 1.26
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
SCF ubiquitin ligases in the maintenance of genome stability. Trends Biochem Sci (2011) 1.21
Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des (2013) 1.19
Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis (2012) 1.17
The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One (2012) 1.15
Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets (2013) 1.14
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res (2014) 1.13
Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues. J Biol Chem (2011) 1.08
Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal (2014) 1.06
Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol Oncol (2012) 1.05
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res (2014) 1.04
Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics (2011) 1.02
Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response. J Immunol (2012) 0.98
Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther (2013) 0.96
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell (2012) 0.95
Inhibition of neddylation represses lipopolysaccharide-induced proinflammatory cytokine production in macrophage cells. J Biol Chem (2012) 0.94
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther (2012) 0.94
New molecular targets in mantle cell lymphoma. Semin Cancer Biol (2011) 0.92
MLN4924 is an efficient inhibitor of NEDD8 conjugation in plants. Plant Physiol (2011) 0.91
Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia (2012) 0.91
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist (2012) 0.90
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood (2016) 0.90
Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis (2014) 0.89
Molecular targeted approaches in mantle cell lymphoma. Semin Hematol (2011) 0.88
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol Cancer Ther (2011) 0.87
Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases. Cell Res (2013) 0.87
Suppression of glioblastoma by targeting the overactivated protein neddylation pathway. Neuro Oncol (2015) 0.87
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia (2015) 0.87
Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma. Cell Death Dis (2014) 0.86
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget (2014) 0.86
Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol (2016) 0.85
NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog (2015) 0.84
A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep (2012) 0.84
Ubiquitin-proteasome system, a new anti-tumor target. Acta Pharmacol Sin (2013) 0.83
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.83
Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol (2014) 0.83
Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. Oncotarget (2014) 0.83
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. Cell Div (2016) 0.82
MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis. Br J Pharmacol (2015) 0.82
Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases. Transl Oncol (2012) 0.82
The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer. Mol Cell Proteomics (2014) 0.82
Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. Cancer Biol Ther (2015) 0.82
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. PLoS One (2014) 0.81
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discov (2015) 0.81
When ubiquitin meets NF-κB: a trove for anti-cancer drug development. Curr Pharm Des (2013) 0.81
MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ (2015) 0.81
Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics (2013) 0.81
Protein ubiquitination in lymphoid malignancies. Immunol Rev (2015) 0.80
MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma. Oncotarget (2016) 0.80
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. Int J Oncol (2014) 0.80
A metal-based inhibitor of NEDD8-activating enzyme. PLoS One (2012) 0.79
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy. Am J Ther (2012) 0.79
Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence. PLoS One (2013) 0.79
Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity. ACS Med Chem Lett (2011) 0.79
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget (2016) 0.79
Broad and potent antiviral activity of the NAE inhibitor MLN4924. Sci Rep (2016) 0.79
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget (2016) 0.79
Inhibiting the protein ubiquitination cascade by ubiquitin-mimicking short peptides. Org Lett (2012) 0.78
Hepatic deficiency of COP9 signalosome subunit 8 induces ubiquitin-proteasome system impairment and Bim-mediated apoptosis in murine livers. PLoS One (2013) 0.78
Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis (2015) 0.78
The histological classification of diffuse large B-cell lymphomas. Semin Hematol (2015) 0.77
Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep (2016) 0.76
p97/VCP promotes Cullin-RING-ubiquitin-ligase/proteasome-dependent degradation of IκBα and the preceding liberation of RelA from ubiquitinated IκBα. J Cell Mol Med (2015) 0.76
Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine (2016) 0.76
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Invest New Drugs (2016) 0.76
NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev (2016) 0.76
Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications. Cytotechnology (2015) 0.76
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood (2015) 0.75
Role of E3 ubiquitin ligases in gastric cancer. World J Gastroenterol (2015) 0.75
Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. Oncotarget (2017) 0.75
Perturbation of neddylation-dependent NF-κB responses in the intestinal epithelium drives apoptosis and inhibits resolution of mucosal inflammation. Mol Biol Cell (2016) 0.75
MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. Am J Cancer Res (2015) 0.75
Understanding drug-cytokine synergistic toxicity. Cell Death Dis (2015) 0.75
Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1. J Virol (2015) 0.75
Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. Proc Natl Acad Sci U S A (2017) 0.75
Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications. Am J Clin Exp Immunol (2014) 0.75
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Invest New Drugs (2016) 0.75
11β-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. J Pathol (2016) 0.75
Induction of cell senescence by targeting to Cullin-RING Ligases (CRLs) for effective cancer therapy. Int J Biochem Mol Biol (2012) 0.75
Inhibition of Vpx-Mediated SAMHD1 and Vpr-Mediated Host Helicase Transcription Factor Degradation by Selective Disruption of Viral CRL4 (DCAF1) E3 Ubiquitin Ligase Assembly. J Virol (2017) 0.75
The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.75
Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity. Cell Death Dis (2016) 0.75
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol (2017) 0.75
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev (2010) 6.35
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 5.10
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res (2005) 4.84
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2013) 4.26
The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy (2005) 4.02
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
Aggressive lymphomas. N Engl J Med (2010) 3.86
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev (2006) 3.49
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov (2006) 3.27
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov (2010) 2.90
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 2.90
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell (2010) 2.64
Obstacles to conducting epidemiological research in the UK general population. BMJ (2004) 2.59
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell (2007) 2.46
Pathogenesis of human B cell lymphomas. Annu Rev Immunol (2012) 2.44
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol (2002) 2.37
Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol (2004) 2.35
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res (2010) 2.27
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
ARL1, a LOB-domain protein required for adventitious root formation in rice. Plant J (2005) 2.24
Validation of the diagnosis of autism in general practitioner records. BMC Public Health (2004) 2.22
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood (2005) 2.19
Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A (2007) 2.10
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 2.04
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2010) 2.04
MMR vaccination and pervasive developmental disorders: a case-control study. Lancet (2004) 2.02
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol (2006) 2.02